This finding indicates that calpain-2 plays a crucial role in mediating the hTau-induced α4 nAChR degradation, which not only present direct evidence to link tau abnormality to cholinergic impairments in AD, but also provide potential drug target (calpain-2) for tau-related treatment. This evidence concerns the gene MAPT and Alzheimer disease.